298 related articles for article (PubMed ID: 38762725)
21. CSF Aβ
Lim YY; Yassi N; Bransby L; Ayton S; Buckley RF; Eratne D; Velakoulis D; Li QX; Fowler C; Masters CL; Maruff P
Neurobiol Aging; 2023 Sep; 129():209-218. PubMed ID: 37399739
[TBL] [Abstract][Full Text] [Related]
22. Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients.
Mendes AJ; Ribaldi F; Lathuiliere A; Ashton NJ; Zetterberg H; Abramowicz M; Scheffler M; Assal F; Garibotto V; Blennow K; Frisoni GB
Alzheimers Res Ther; 2024 May; 16(1):110. PubMed ID: 38755703
[TBL] [Abstract][Full Text] [Related]
23. Initial levels of β-amyloid and tau deposition have distinct effects on longitudinal tau accumulation in Alzheimer's disease.
Cai Y; Du J; Li A; Zhu Y; Xu L; Sun K; Ma S; Guo T;
Alzheimers Res Ther; 2023 Feb; 15(1):30. PubMed ID: 36750884
[TBL] [Abstract][Full Text] [Related]
24. Association of Brain Amyloid-β With Slow Gait in Elderly Individuals Without Dementia: Influence of Cognition and Apolipoprotein E ε4 Genotype.
Nadkarni NK; Perera S; Snitz BE; Mathis CA; Price J; Williamson JD; DeKosky ST; Klunk WE; Lopez OL
JAMA Neurol; 2017 Jan; 74(1):82-90. PubMed ID: 27842173
[TBL] [Abstract][Full Text] [Related]
25. Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults.
Buckley RF; Mormino EC; Rabin JS; Hohman TJ; Landau S; Hanseeuw BJ; Jacobs HIL; Papp KV; Amariglio RE; Properzi MJ; Schultz AP; Kirn D; Scott MR; Hedden T; Farrell M; Price J; Chhatwal J; Rentz DM; Villemagne VL; Johnson KA; Sperling RA
JAMA Neurol; 2019 May; 76(5):542-551. PubMed ID: 30715078
[TBL] [Abstract][Full Text] [Related]
26. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease.
Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Lantero Rodríguez J; Snellman A; Suárez-Calvet M; Blennow K; Zetterberg H; Schöll M;
JAMA Neurol; 2021 Apr; 78(4):396-406. PubMed ID: 33427873
[TBL] [Abstract][Full Text] [Related]
27. Longitudinal associations of serum biomarkers with early cognitive, amyloid and grey matter changes.
De Meyer S; Blujdea ER; Schaeverbeke J; Reinartz M; Luckett ES; Adamczuk K; Van Laere K; Dupont P; Teunissen CE; Vandenberghe R; Poesen K
Brain; 2024 Mar; 147(3):936-948. PubMed ID: 37787146
[TBL] [Abstract][Full Text] [Related]
28. Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition.
Rauchmann BS; Schneider-Axmann T; Perneczky R;
J Neurol Neurosurg Psychiatry; 2021 Dec; 92(12):1289-1295. PubMed ID: 34187867
[TBL] [Abstract][Full Text] [Related]
29. Pathologic and cognitive correlates of plasma biomarkers in neurodegenerative disease.
Cousins KAQ; Phillips JS; Das SR; O'Brien K; Tropea TF; Chen-Plotkin A; Shaw LM; Nasrallah IM; Mechanic-Hamilton D; McMillan CT; Irwin DJ; Lee EB; Wolk DA
Alzheimers Dement; 2024 Jun; 20(6):3889-3905. PubMed ID: 38644682
[TBL] [Abstract][Full Text] [Related]
30. APOE ε4 carrier status modifies plasma p-tau181 concentrations in cognitively healthy super-seniors.
Cooper JG; Ghodsi M; Stukas S; Leach S; Brooks-Wilson A; Wellington CL
Alzheimers Dement; 2024 Jun; 20(6):4373-4380. PubMed ID: 38752508
[TBL] [Abstract][Full Text] [Related]
31. Sex and APOE ε4 carrier effects on atrophy, amyloid PET, and tau PET burden in early-onset Alzheimer's disease.
Nemes S; Logan PE; Manchella MK; Mundada NS; La Joie R; Polsinelli AJ; Hammers DB; Koeppe RA; Foroud TM; Nudelman KN; Eloyan A; Iaccarino L; Dorsant-Ardón V; Taurone A; Thangarajah M; Dage JL; Aisen P; Grinberg LT; Jack CR; Kramer J; Kukull WA; Murray ME; Rumbaugh M; Soleimani-Meigooni DN; Toga A; Touroutoglou A; Vemuri P; Atri A; Day GS; Duara R; Graff-Radford NR; Honig LS; Jones DT; Masdeu J; Mendez MF; Musiek E; Onyike CU; Riddle M; Rogalski E; Salloway S; Sha SJ; Turner RS; Wingo TS; Womack KB; Wolk DA; Rabinovici GD; Carrillo MC; Dickerson BC; Apostolova LG;
Alzheimers Dement; 2023 Nov; 19 Suppl 9(Suppl 9):S49-S63. PubMed ID: 37496307
[TBL] [Abstract][Full Text] [Related]
32. Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease.
Quiroz YT; Sperling RA; Norton DJ; Baena A; Arboleda-Velasquez JF; Cosio D; Schultz A; Lapoint M; Guzman-Velez E; Miller JB; Kim LA; Chen K; Tariot PN; Lopera F; Reiman EM; Johnson KA
JAMA Neurol; 2018 May; 75(5):548-556. PubMed ID: 29435558
[TBL] [Abstract][Full Text] [Related]
33. Apolipoprotein E epsilon4 does not modulate amyloid-β-associated neurodegeneration in preclinical Alzheimer disease.
Desikan RS; McEvoy LK; Holland D; Thompson WK; Brewer JB; Aisen PS; Andreassen OA; Hyman BT; Sperling RA; Dale AM;
AJNR Am J Neuroradiol; 2013 Mar; 34(3):505-10. PubMed ID: 22976236
[TBL] [Abstract][Full Text] [Related]
34. Associations among plasma, MRI, and amyloid PET biomarkers of Alzheimer's disease and related dementias and the impact of health-related comorbidities in a community-dwelling cohort.
Rudolph MD; Sutphen CL; Register TC; Whitlow CT; Solingapuram Sai KK; Hughes TM; Bateman JR; Dage JL; Russ KA; Mielke MM; Craft S; Lockhart SN
Alzheimers Dement; 2024 Jun; 20(6):4159-4173. PubMed ID: 38747525
[TBL] [Abstract][Full Text] [Related]
35. Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies.
Bolsewig K; van Unnik AAJM; Blujdea ER; Gonzalez MC; Ashton NJ; Aarsland D; Zetterberg H; Padovani A; Bonanni L; Mollenhauer B; Schade S; Vandenberghe R; Poesen K; Kramberger MG; Paquet C; Bousiges O; Cretin B; Willemse EAJ; Teunissen CE; Lemstra AW;
Neurology; 2024 Jun; 102(12):e209418. PubMed ID: 38830138
[TBL] [Abstract][Full Text] [Related]
36. Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer's Disease.
Lantero-Rodriguez J; Salvadó G; Snellman A; Montoliu-Gaya L; Brum WS; Benedet AL; Mattsson-Carlgren N; Tideman P; Janelidze S; Palmqvist S; Stomrud E; Ashton NJ; Zetterberg H; Blennow K; Hansson O
Mol Neurodegener; 2024 Feb; 19(1):19. PubMed ID: 38365825
[TBL] [Abstract][Full Text] [Related]
37. A Non-APOE Polygenic Risk Score for Alzheimer's Disease Is Associated With Cerebrospinal Fluid Neurofilament Light in a Representative Sample of Cognitively Unimpaired 70-Year Olds.
Skoog I; Kern S; Najar J; Guerreiro R; Bras J; Waern M; Zetterberg H; Blennow K; Zettergren A
J Gerontol A Biol Sci Med Sci; 2021 May; 76(6):983-990. PubMed ID: 33512503
[TBL] [Abstract][Full Text] [Related]
38. APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern.
Risacher SL; Kim S; Nho K; Foroud T; Shen L; Petersen RC; Jack CR; Beckett LA; Aisen PS; Koeppe RA; Jagust WJ; Shaw LM; Trojanowski JQ; Weiner MW; Saykin AJ;
Alzheimers Dement; 2015 Dec; 11(12):1417-1429. PubMed ID: 25960448
[TBL] [Abstract][Full Text] [Related]
39. Effect of APOE ε4 genotype on amyloid-β and tau accumulation in Alzheimer's disease.
Baek MS; Cho H; Lee HS; Lee JH; Ryu YH; Lyoo CH
Alzheimers Res Ther; 2020 Oct; 12(1):140. PubMed ID: 33129364
[TBL] [Abstract][Full Text] [Related]
40. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease.
Pereira JB; Janelidze S; Smith R; Mattsson-Carlgren N; Palmqvist S; Teunissen CE; Zetterberg H; Stomrud E; Ashton NJ; Blennow K; Hansson O
Brain; 2021 Dec; 144(11):3505-3516. PubMed ID: 34259835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
